Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer

Technology appraisal guidance
Reference number: TA192
Published: 28 July 2010

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - clarification regarding potential issue with the economic model

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - Liverpool Reviews and Implementation Group (LRiG) comments on additional information provided by the manufacturer-post 2nd AC meeting held on 4 March 2010
Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - Liverpool Reviews and Implementation Group (LRiG) comments on additional information provided by the manufacturer (addendum 9 March 2010)
Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - letter sent by NICE to AstraZeneca 10 March 2010
Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - AstraZeneca letter of response 11 March 2010

This page was last updated: 25 May 2010